Van ECK Associates Corp Has $6.90 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Van ECK Associates Corp cut its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 9.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 122,842 shares of the medical research company's stock after selling 13,023 shares during the quarter. Van ECK Associates Corp owned 0.07% of Exact Sciences worth $6,902,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after buying an additional 7,873 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Exact Sciences by 10.9% in the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock worth $169,924,000 after acquiring an additional 245,980 shares during the last quarter. Bellevue Group AG lifted its holdings in Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock worth $98,738,000 after acquiring an additional 290,585 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Exact Sciences by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company's stock valued at $88,017,000 after acquiring an additional 45,015 shares during the period. Finally, Groupama Asset Managment bought a new position in shares of Exact Sciences during the third quarter valued at approximately $821,000. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Ratings Changes

EXAS has been the topic of several recent research reports. Citigroup cut their price target on Exact Sciences from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Craig Hallum cut their target price on Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. TD Cowen upped their price target on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Barclays cut their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Bank of America decreased their target price on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $72.06.

Exact Sciences Price Performance

EXAS stock traded down $0.25 during trading hours on Friday, hitting $49.26. 3,339,540 shares of the stock traded hands, compared to its average volume of 2,338,169. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The stock has a 50-day simple moving average of $54.91 and a 200 day simple moving average of $59.99. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The company has a market cap of $9.12 billion, a P/E ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 4.97%. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Equities analysts forecast that Exact Sciences Co. will post -0.59 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.